Clinical trials
Phase 1/2 Fatigue trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
27 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2005 | 1 |
| 2006 | 2 |
| 2007 | 2 |
| 2008 | 3 |
| 2011 | 2 |
| 2013 | 1 |
| 2014 | 4 |
| 2016 | 1 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2023 | 2 |
| 2026 | 4 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 16 |
| Terminated | 5 |
| Not yet recruiting | 2 |
| Withdrawn | 1 |
| Recruiting | 1 |
| Active, not recruiting | 1 |
| Unknown status | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Sheba Medical Center | 2 |
| Consorzio Oncotech | 1 |
| Fox Chase Cancer Center | 1 |
| Jason Allen, Ph.D. | 1 |
| Johns Hopkins University | 1 |
| Logan College of Chiropractic | 1 |
| M.D. Anderson Cancer Center | 1 |
| Mitosynergy LLC | 1 |
| Nambudripad's Allergy Research Foundation | 1 |
| National Institute of Nursing Research (NINR) | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Fatigue | 27 |
| Multiple Sclerosis | 4 |
| Breast Neoplasms | 2 |
| Neoplasms | 2 |
| Parasomnias | 2 |
| Amyotrophic Lateral Sclerosis | 1 |
| Body Weight Changes | 1 |
| Brain Injuries, Traumatic | 1 |
| Carcinoma, Renal Cell | 1 |
| Cognitive Dysfunction | 1 |
Trials
Showing 51 to 27 of 27. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.